|
|
| Blue
Bell, PA – October 24, 2007 – |
|
VGX Pharmaceuticals, Inc., a leading manufacturer
of cGMP-grade DNA plasmids, announced today that it has expanded its manufacturing
capacity with the installation and testing of a new 500-liter scale fermentor
in its cGMP manufacturing facility in The Woodlands, Texas. The new fermentor
gives VGX significantly more flexibility than its current 100-liter production
scale.
In addition to manufacturing DNA plasmids for its own product development
purposes, VGX has been offering contract manufacturing services to outside
client organizations with the flexible, state of the art facility used
for research, development, and clinical supply. VGX-manufactured products
have passed rigorous reviews by several international regulatory agencies.
“This upgrade represents the initial phase of enhancing VGX’s
capabilities to manufacture DNA plasmids for clinical and eventually commercial
applications,” said Dr. J. Joseph Kim, President and CEO of VGX.
“We will continue to enhance our manufacturing capabilities and
capacity to meet the increasing demand for our own DNA-based vaccine and
therapy product candidates as well as those of our clients.”
VGX Pharmaceuticals has initiated IND-enabling pre-clinical toxicology
studies for three of its DNA plasmid-based product candidates. The candidates
include vaccines for human papilloma virus for the treatment of cervical
cancer (VGX-3100) and avian influenza (VGX-3400), and a therapeutic based
on human growth hormone releasing hormone (VGX-3200) for cancer-related
cachexia. The Company expects to file Investigational New Drug Applications
(INDs) for all three products by June 2008.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecule and
biologic product candidates for the treatment of infectious diseases, cancer,
and inflammatory diseases. The Company's clinical development programs include
PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection,
both of which are currently in Phase II clinical trials. In addition, VGX
is planning to initiate Phase I clinical studies for VGX-1027, its lead
compound for inflammatory diseases. VGX's research pipeline includes a new
generation of DNA vaccines and therapeutics as well as CELLECTRA™,
a patented DNA delivery device. The product candidates and technology programs
are protected by the Company's extensive global intellectual property portfolio.
More information about VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
